Allergan PLC took its pledge last fall to limit drug price increases about as literally as it gets, according to a new analysis from Evercore ISI analyst Umer Raffat.

The company has “technically” limited its hikes with “almost all the price increases” coming in at under 10%, as promised, Raffat said.

But many of the company’s price increases came in just below that benchmark, at 9.5%, on the pricey glaucoma drug Lumigan, dementia caused by Alzheimer’s disease drug Namenda XR, intestine ulcer drug Carafate, irritable bowel syndrome drug Linzess, depression drug Fetzima and intrauterine device Liletta.

The lowest price increase on an analysis done by Raffat was a 5% increase on the antibiotic Teflaro.

Read more: Allergan offers a rare pharmaceutical company promise: limits on drug-price increases

“These price increases are consistent with our #socialcontract,” Allergan said on Twitter, responding to criticism.

The company said, consistent with its pledge, price increases for 2017 remained in the single digits, and said net price increases — which include negotiated discounts and rebates — from the prior year were expected to be about 2% to 3%.

See: Big pharma won’t stop raising prices in 2017 — it’ll just do it smarter